We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Factory Location: Changsha high-tech development zone, 100 foot cloud road brought science park 14 layer 5, 501
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: L/L
SNI mice (Knock out the TALEN gene), have completed the humanization model of xenograft (PDX) derived from lung cancer, leukemia, liver cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer and other cancer patients; and published 20 high-level SCI papers with an impact factor of over 100. There are 7 pre-clinical evaluation drugs, and currently 3 drugs have obtained clinical trial approval through clinical approval.
NSIN mice (Knock out Fah at NSI), no fur, transplanted tumors are easier to observe and measure, and compared with other similar immunodeficient mice, less cell dose is required for modeling, tumor formation is better, living body imaging is reduced, and tumors are detected more quickly and accurately. .
NSIF mice (Knock out Foxn1 at NSI), This line of mice controls NTBC uptake to induce hepatocyte injury in mice, and is highly efficient for human normal liver tissue transplantation. The humanized liver mouse model established by NSIF mice can mimic the metabolism of drugs in humans. , the metabolism and toxicity test of the drug.